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KAJIAN INTERAKSI DRUG-NUTRIEN SERTA KESERASIAN FIZIKOKIMIA 
SEFTAZIDIM, SEFOTAKSIM DAN SEFEPIM DALAM ADMIKSTUR NUTRIEN 
NEONAT TOTAL MENGGUNAKAN HPLC 
 
ABSTRAK 
 
Campuran keseluruhan nutrient (TNA)  teleh digunakan secara meluas sebagai kaedah terapeutik 
dalam pengurusan pesakit kekurangan zat makanan yang menerima nutrisi parenteral sejak 
kelulusan untuk mencampur emulsi lemak intravena dengan pelbagai larutan asid amino dan 
dekstrosa. Kelebihan TNAs termasuk rawatan nutrisi dirumah, kurang risiko jangkitan, 
memerlukan kurang kakitangan kejururawatan, tidak memerlukan tambahan bendalir untuk 
mencairkan drug, penurunan kos pemberian berbanding dengan kaedah piggyback konvensional 
dan peningkatan toleransi intravena emulsi lemak dalam neonat. Penambahan antibiotik ke 
dalam TNAs sering menimbulkan persoalan mengenai kestabilan antibiotik untuk tempoh yang 
lebih lama, seperti 24 jam. Malangnya, data mengenai kesetabilan TNAs di dalam/dengan 
antibiotik jarang diperolihi. Kajian ini bertujuan untuk menilai kestabilan dan keserasian 
antibiotik (ceftazidime, cefepime dan cefotaxime) dalam TNAs. Kesetabilan dan keserasian 
diukur secara kimia menggunakan HPLC berkelajuan tinggi (Prominence UFLC model LC-
20AD, Shimadzu, Columbia, Amerika Syarikat) menggunakan kaedah yang dibangunkan sendiri 
dan telah disahkan. Jangka hayat dan peratusan antibiotik yang masih ada dalam semua 
formulasi / sampel diukur pada selang masa yang berbeza (H0, H4, H8, H16 dan H24) dengan 
menggunakan kaedah di atas. Kepekatan komponen TNAs seperti makronutrien dan 
mikronutrien yang digunakan dalam kajian ini adalah mengikut berat badan normal neonat iaitu 
3 kg. Kajian ini menilai kesan pelbagai kepekatan makronutrien tersebut dalam / dengan 
antibiotik. Setiap antibiotik, 48 formulasi TNAs telah disediakan dalam kombinasi makronutrien 
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(dekstrosa, asid amino dan lemak) dan mikronutrien (vitamin, elektrolit dan unsur surih) yang 
berbeza. Kesetabilan formulasi telah dinilai bagi parameter fiziko-kimia seperti pH, saiz titisan, 
potensi zeta, pemendakan, pembekuan, penggumpalan dan kepekatan natrium, kalium serta 
kepekatan drug. Kajian ini telah dijalankan pada suhu bilik (25 ± 2°C) dan sampel telah 
dikumpulkan pada 0, 4, 8, 16 dan 24 jam masing-masing. Kepekatan antibiotik dalam sampel 
dianalisis dengan menggunakan kaedah HPLC yang telah disahkan di atas. Kajian mendapati 
ceftazidime dan cefepime stabil sehingga 16 jam manakala cefotaxime pada stabil sehingga 24 
jam di semua formulasi TNAs dan seterusnya meluluh melebihi daripada 10% masing-masing. 
Hasil keserasian fiziko-kimia menunjukkan bahawa tidak terdapat sebarang perubahan signifikan 
dalam pH, saiz titisan, potensi zeta dan kepekatan natrium dan kalium dalam semua sediaan 
(semua p >0.05). Di samping itu, tidak terdapat pembekuan dan pemendakan signifikan 
diperhatikan dalam tempoh tersebut. Kesimpulannya, kajian ini menunjukkan bahawa 
ceftazidime dan cefepime adalah serasi dan stabil selama 16 jam di dalam / dengan TNAs 
manakala cefotaxime serasi dan stabil selama 24 jam di dalam / dengan TNAs. 
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INVESTIGATION OF DRUG NUTRIENT INTERACTIONS AND 
PHYSICOCHEMICAL COMPATIBILITIES OF CEFTAZIDIME, 
CEFOTAXIME AND CEFEPIME IN NEONATAL TOTAL NUTRIENT 
ADMIXTURES USING HPLC 
 
ABSTRACT 
 
Total nutrient admixtures (TNAs) is widely used therapeutic intervention in the management of 
malnourished patients receiving parenteral nutrition since the approval of admixing intravenous 
fat emulsions with various amino acids and dextrose solutions. The advantages of TNAs include 
home nutrition therapy, less risk of infections, less need of nursing staff, no need of additional 
fluids to dilute the drugs, decreased administration costs compared with the conventional 
piggyback method and increased tolerance of intravenous fat emulsions in neonates. Addition of 
antibiotics to the TNAs often raises question of stability of the antibiotics over longer periods 
e.g. 24 hours. Unfortunately, very little data about TNAs stability in/with antibiotics is available. 
This study was aimed to evaluate the stability and compatibility of antibiotics (ceftazidime, 
cefepime and cefotaxime) in TNAs. The stability and compatibility were measured chemically, 
by using a high-speed HPLC (Prominence UFLC model LC-20AD, Shimadzu, Columbia, USA) 
based on newly developed and validated methods. Shelf life and percentage of remaining 
antibiotics in all formulations were measured at different time intervals (H0, H4, H8, H16 and 
H24) by using the above methods. The concentrations of TNAs’ components i.e. macronutrients 
and micronutrients used in the study were according to the normal body weight of neonates i.e. 3 
kg neonates. The study evaluated the effect of varied concentrations of macronutrients in/with 
antibiotics. For each antibiotic, forty-eight TNAs formulations were prepared in different 
combinations of macronutrients (dextrose, amino acids and fats) and micronutrients (vitamins, 
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and trace elements). The stability of the formulations were evaluated for various physico-
chemical parameters such as pH, globule size, zeta potential, precipitation, flocculation, 
coalescence and concentrations of sodium, potassium and drug concentrations. The experiments 
were carried out at room temperature (25±2°C) and samples were collected at 0, 4, 8, 16 and 24 
hours respectively. Antibiotic concentrations in the samples were analyzed by using the newly 
developed and validated HPLC methods. SPE was used by modification of the mobile phase and 
washing solvents in different ratios to achieve better accuracy, precision, linearity, earlier 
retention times, clear elution and recovery. The study showed that ceftazidime and cefepime 
were stable for up to 16 hours while cefotaxime was stable for up to 24 hours in all TNAs 
formulations and there after degraded more than 10% respectively. Physico-chemical 
compatibility results showed that there were no significant changes in pH, globules size, zeta 
potential and concentrations of sodium and potassium in all of the formulations (all p >0.05). In 
addition, there was no precipitation or flocculation observed in any of the formulation. The 
newly developed HPLC methods were able to detect selected cephalosporins more accurately, 
precisely, effectively and efficiently. In conclusion, this study showed that ceftazidime and 
cefepime were compatible and stable for 16 hours in/with TNAs while cefotaxime was 
compatible and stable for 24 hours in/with TNAs. 
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CHAPTER ONE 
GENERAL INTRODUCTION  
1.1. Introduction 
Parenteral nutrition (PN) or total parenteral nutrition (TPN) is an intravenous administration of 
amino acids, glucose, lipids, electrolytes, vitamins and trace elements (Nelson et al., 1986). In 
individuals who are unable to tolerate food by oral or enteral route, total parenteral nutrition is 
the best alternative route to sustain their lives. PN is often needed as an adjunct in cancer therapy 
and in many particular situations, i.e. when a patient is unable to take adequate oral calories for 
more than a week, or has poor absorptive capacity after surgery, or has a fistula, acute hepatic or 
renal failure, or an inflammatory bowel disease (Siow, 2008). Parenteral nutrition is also a 
standard practice for providing exogenous nutrients to the patients having several diseases in 
order to improve their nutritional status and to avoid any catheter related infection (Alfieri et al., 
1998). Composition of PN admixtures primarily depends on the individual needs of nutrients and 
electrolytes. The decision to start PN therapy and the choice of the PN admixtures should be 
tailored to the patient’s diagnosis and nutritional status to avoid over or under nutrition (Iacobelli 
et al., 2010; Leung, 1995; Vanek et al., 1997; Verma et al., 2010; Weiler et al., 2006). 
 
PN for children is different from adults because it contains relatively more electrolytes and other 
nutrients (Iacobelli et al., 2010). Prime goals of nutritional support during first few days of 
postnatal life are, to maintain the liquid balance, to normalize glycemia and to maintain levels of 
electrolytes and minerals in the body. In general, the liquid needs of large immature neonates 
vary from 90 to 140 mL/kg/day when they are in radiant warmers while 80 to 120 ml/kg/day 
when they are in incubators. Liquids are normally administered to immature neonates as 5% or 
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7.5% solutions of glucose, to avoid glycemic disorders which are common in the first days of life 
(Diekmann et al., 2005; Falk, 1998; Jadhav et al., 2007; Pauls et al., 1998; Ronchera-Oms et al., 
1995).  Nowadays, it is desirable to supply PN admixtures’ components in a single bag called 
All-in-One Total Parenteral Nutrition Admixtures (AIO TPN Admixtures) or Total Nutrient 
Admixtures (TNAs).  
 
TNAs have become an extensively used therapeutic tool to treat malnourished patients receiving 
parenteral nutrition after the approval of admixing intravenous fat emulsions with dextrose 
solutions and various amino acids. The advantages of TNAs include decreased administration 
costs compared with the conventional piggyback method for infusion of intravenous fat 
emulsions into parenteral nutrient solutions and increased tolerance of intravenous fat emulsions 
in neonates when the fat is infused over a period of 24 hours. Microbial growth studies have also 
demonstrated a reduction in microbial growth in the TNAs when compared with intravenous fat 
emulsions alone infused over 24 hours (Driscoll et al., 2000; Driscoll et al., 2007;  Eskew, 1987; 
Gilbert et al., 1986; Simmons et al., 1982). 
 
Advantages of TNAs are, number of nurse handlings is lowered, the risk of thrombophlebitis is 
reduced, therapeutic errors are minor and all nutrients are supplied continuously over the day. 
TNAs are complex nutrients solutions containing lipid emulsions, which need sterility, stability 
and free from precipitates. In TNAs numerous components (amino acids, carbohydrates, lipids, 
water for injection, electrolytes, trace elements and vitamins) interact according to different 
reactions which are fairly less known to date. There are many factors like biphasic characteristic 
of lipid emulsion which can affect the compatibility of TNAs and can cause physicochemical 
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instability of TNAs. Thus a careful quality control during compounding as well as in clinical 
practice is vital. In contrast to TNAs for adults, hardly there is any information available about 
the stability of neonatal TNAs which contain more nutrients (Hardin, 1993; Imrie et al., 2002; 
Lorenz, 2008; Porcelli and Sisk, 2002; Rigo and Senterre, 2006).  
 
The limitations of the TNAs are related to the lack of information regarding stability when 
different amino acids are used or varying concentrations of electrolytes or other additives are 
admixed with the emulsion system. The predominant factors affecting emulsion particle size, or 
stability are pH and increased electrolyte concentration. The significance of emulsion globule 
size has been established by reports of adverse reactions associated with the infusion of particles 
greater than 6 µm in size (Driscoll et al., 2007). As pH varies with different crystalline amino 
acid formulations and concentrations, the stability of each amino acid product must be tested 
with a given intravenous fat emulsion in various concentrations. For better clinical significance, 
various concentrations of electrolytes and minerals are added to the TNAs to make them more 
appropriate for individual patients (Bullock et al., 1992, D'Angio et al., 1987; Driscoll et al., 
2007; Harrie et al., 1986; Lee et al., 2003; Mershon et al., 1986; Sayeed et al., 1986; Simmons et 
al., 1982). 
 
Although the improvement of multi compartment bags has amplified the shelf-life of TNAs but 
TNA therapy is still having several metabolic risks, infections and mechanical complications. In 
addition, the physicochemical instability and risks of substrate precipitation may make TNAs 
more obscure. Parts of these complications can be avoided by stern pharmaceutical procedures 
and clinical guidelines. It is also very important that all TNAs formulas/ratios should be prepared 
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according to strict pre-established procedures which can reinforce quality control principles and 
guidelines (Batani et al., 2007; Dudrick, 2009, Maisonneuve et al., 2004; Menne et al., 2008). 
 
The addition of medications and other additives to TNAs has become common practice in order 
to reduce intravenous catheter manipulations and minimizing the risk of contamination 
(Atkinson, 2001; Franasois et al., 1997; McGuire et al., 2004). Therefore addition of antibiotics 
to TNAs before the start of the infusions would be preferable in order to lessen various infections 
which may often cause problems particularly in very small newborns that have immature 
immune systems and reduced muscle mass. Moreover, by adding antibiotics to the fluids, which 
are infused via a pump, it is quite possible to maintain a higher steady-state concentration than 
the minimal inhibitory concentration for most bacterial strains. As an example amino glycosides 
administered in this pattern have shown a high cure rate in adults as well as in neonates (Bodey 
et al., 1995; Pierre et al., 2009). 
 
Addition of antimicrobials and antibiotics to the TNAs to treat central catheter-related infections 
has shown a number of practical advantages like (i) the TNAs containing antimicrobials can be 
given during home nutrition therapy (ii) manipulations involving the catheter are not needed to 
administer the antimicrobials/antibiotics hence there is less risk of infections and less need of 
nursing staff (iii) there is no need for additional fluids to dilute the antimicrobials or antibiotics, 
which can be very useful in neonates and infants having fluid restrictions (Forbes, 2004; Tounian 
et al., 1999). 
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Addition of antibiotics to the TNAs often raises question of stability of the antibiotics over 
longer periods e.g. 24 hours. Stability of antibiotics in/with TNAs containing electrolytes, 
carbohydrates and protein solutions has been examined rather comprehensively, whereas the 
stability and compatibility of antibiotics in combination or alone in synthetic amino acid 
solutions, carbohydrates together with fats has only been studied by one or two groups (Anthony 
and Rubin, 1999; Stein, 1999; Wyatt et al., 1972). Unfortunately, nearly all stability studies of 
drugs in pediatric nutrient solutions focus on drug concentrations/availability but not on nutrient 
stability. Above all, data about micronutrient stability after adding medication to pediatric TNAs 
is almost rare in the literature which is vital for the welfare of the patients especially neonates 
and infants. Various issues may be related to micronutrients and macronutrients’ physical and 
chemical instability in TNAs together with medications (Forbes, 2004; Hardin, 1993; Leung et 
al., 1995). 
 
Stability testing of pharmaceuticals is essential for three reasons. First, patient safety by assuring 
that patient receives a uniform dose of a drug throughout the shelf life of formulation. Second, to 
meet legal requirements concerning with identity, strength, purity and quality of a drug. Third, to 
control economic repercussions involved in developing and marketing unstable products. 
Currently, around the globe, it is a common practice to administer different antibiotics especially 
cephalosporins in/with PN admixtures in order to treat various infections or diseases. Thus it is 
very important to check their stability in/with these TNAs in order to administer a precise dose 
and to assure that patients will receive a uniform dose throughout the shelf life of formulations. 
To date there is no sufficient literature available that can confidently describe the stability of 
some commonly used antibiotics like cephalosporins in/with PN admixtures. This project is 
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especially aimed to check the stability and compatibility of commonly used antibiotics 
(ceftazidime, cefotaxime and cefepime) in/with TNAs.  
 
1.2. Literature review 
1.2.1. Parenteral nutrition (PN) 
The standard use of parenteral nutrition (PN) in clinical practice started in 1968, after Dudrick et 
al., efforts. These pioneers explained that parenteral therapy of amino acids and glucose 
concentrated solutions together with minerals, vitamins and micronutrients may result in more 
growth in children and adults. Initially PN admixtures were administered mostly with amino 
acids and glucose. Now, parenteral nutrition (PN) includes intravenous administration of amino 
acids, glucose, lipids, electrolytes, vitamins and trace elements (Dudrick, 2009, Waitzberg et al., 
2006). 
 
Parenteral nutrition (PN) can be divided into: 
 Total parenteral nutrition (TPN), where all nutrient needs are covered by intravenous way 
without any significant enteral intake. 
 Supplementary parenteral nutrition, where a patient receives some part of his/her food via 
gastrointestinal tract and the rest is infused parenterally (Pertkiewicz et al., 2009). 
 
TPN admixtures are usually referred to as Two-in-One (TIO) or All in- One (AIO) where these 
refer to admixtures that are either 
 
 TIO an aqueous formulation (mixture of dextrose and amino acids free of fat) 
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 AIO infusion which will usually contain all the required PN components, including lipid 
in the form of an emulsion (Barnett et al., 2009). 
 
Nowadays, it is desirable to supply PN from one compartment which is called AIO TPN 
admixtures (All-in-One Total Parenteral Nutrition Admixtures) or TNAs (Total Nutrient 
Admixtures). In this system, all of the individual components (sterile injections or infusions) are 
admixed into a single sterile plastic container, providing the user with a complex pharmaceutical 
formulation in the form of a single easy to use infusion system. Advantages of this system are, 
the number of nurse handlings is lowered, the risk of thrombophlebitis and errors is reduced and 
all nutrients are supplied incessantly over the day (Barnett et al., 2009, Dudrick, 2009). 
 
TNAs are sterile large volume parenteral infusions aseptically prepared from required nutritional 
components (e.g. amino acids, glucose, lipid, electrolytes, trace elements and vitamins). 
Parenteral nutrition (PN) is also an alternative way for patients who cannot eat food or cannot 
meet their caloric needs totally or partially via gastrointestinal route (Gunsar et al., 2010). In all, 
there may be more than 39 individual additives, each of which has its own physicochemical 
characteristics (Kearney et al., 1998). 
 
At the moment in various countries, preparation of TNAs is extensively practiced by their 
hospital pharmacy departments. The foremost objective is to integrate all of the nutritional 
necessities into one infusion bag for administration to the patients on daily basis. TNAs can be 
given long shelf lives i.e. in weeks or in months, depending upon the specific formulation 
(Kearney et al., 1998). Undeniably TNA is a leading development in medical therapy for the 
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provision of energy and other essential nutrients to the seriously ill patients who are unable to 
eat. TNAs feeding significantly reduce both morbidity and mortality in seriously ill medical or 
surgical patients. However, PN feeding often augments the risk of infectious complications 
compared with enteral nutrition (Ling et al., 2010). 
 
Children treated with chemotherapy have a suppressed immune system and are very susceptible 
to infections. It is important to lessen the risk of infections for these patients due to intravenous 
administrations. TNA for children is different from that of adults, because it contains relatively 
more electrolytes or other components. On contrary to TNA for adults, there is very less 
information about the stability of lipids in neonatal TNAs, prepared and administered from one 
compartment (all-in-one). The composition of the TNAs normally depends on the body mass and 
on the phase in the nutrition period. Thus, it should be adapted to individual needs of nutrients 
and electrolytes (Barnett et al., 2009; Koorenhof and Timmer, 1992; Lemons et al., 2001). 
 
1.2.2. Parenteral nutrition in neonates and infants 
Parenteral nutrition is a lifesaving medical intervention for many pediatric patients. Parenteral 
nutrition provides energy for growth and tissue repair when the gastrointestinal tract cannot be 
used due to small stomach capacity, immature gastrointestinal tract and illnesses. This is 
especially true for preterm or low birth weight neonates who represent the highest percentage of 
the pediatric population requiring parenteral nutrition. A small premature infant whose nutrition 
reserve are limited can survive 4-5 days if fed water alone and 11 days if provided with 10% 
dextrose alone (Brine and Ernst, 2004; Hack and Fanaroff, 2000; Oden and Bourgeois, 2000). In 
more recent years, the earlier introduction and more aggressive advancement of PN was shown 
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to be safe and effective, even in the smallest and most immature infants (Thureen and Hay, 
2001). 
 
The neonatal period is a vital interval where nutrition can influence the infant’s growth and 
development. Failure to provide essential nutrients can result in serious conditions, including 
growth retardation, reduced respiratory and cardiac reserve, impaired immune system, impaired 
tissue and muscle functions and neurological deficits (Sedlacek et al., 2006; Wilson et al., 1997). 
The period of 30 weeks of gestational age to 6 months of life is vital for brain development while 
nutrition compromised in this period may cause everlasting loss of brain development. 
Therefore, the nutrient support of the preterm and critically ill infant is extremely important, not 
only for rapid endurance but also for a long-term outcome (Chaudhari and Kadam, 2006, Mermel 
et al., 2001).  
 
It is very difficult to survive for many critically ill preterm infants in their first weeks of life 
because of the infant’s small stomach capacity and immature gastrointestinal tract. In such cases 
parenteral nutrition becomes essential for nutrition support; either as a supplement to enteral 
feedings or as the total source of nutrition (Allwood et al., 1996; Driscoll, 1996; Uuml et al., 
2009). According to ASPEN and ESPEN clinical guidelines, PN in neonates is recommended in 
various diseases i.e. gastrointestinal diseases like significant anomalies of the gastrointestinal 
tract requiring surgery, chronic intractable diarrhea, vomiting, inflammatory bowel disease, 
radiation enteritis, chronic intestinal obstruction or pseudo-obstruction, mucositis, esophageal 
stricture, tracheoesophageal fistula, severe malabsorption, fistula, congenital microvillous 
atrophy, diseases of other organs like hepatic coma, pancreatitis, renal failure, congenital heart 
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disease, severe respiratory disease, various surgical conditions (other than gastrointestinal tract) 
like preoperative support, postoperative support, severe burn and trauma, numerous psychiatric 
disorders like anorexia nervosa, neoplasia and the patients with mal enteral nutrition (Allwood et 
al., 1996; Driscoll, 1996; Koletzko et al., 2005; Lee, 1996; Mehta et al., 2009; Uuml et al., 
2009). 
 
1.2.3. Parenteral nutrition in Malaysia 
Firstly parenteral nutrition services in Malaysia were introduced in 1986 at two hospitals, 
Hospital USM Kelantan and Hospital Pulau Pinang. Since then, there are numerous reported 
studies on PN practice in Malaysian hospitals presented in various local and international 
seminars and conferences (Batani et al., 2007). 
 
1.2.4. Components of TNAs 
The proportions and mix of components of TNAs used for intravenous nutrition can vary 
considerably depending upon the patient’s nutritional status and underlying medical or surgical 
conditions. The components available for TNAs are macronutrients and micronutrients and are 
detailed below (Cooke and Griffin, 2009; Ehrenkranz et al., 2006; Rigo et al., 2001). 
 
1.2.4 (a). Macronutrients 
Macronutrients constitute the majority of an individual’s diet, “thereby supplying energy, and the 
essential nutrients that are needed for growth, maintenance, and activity”. Macronutrients include 
carbohydrates, proteins and fats. Carbohydrates, proteins, and fats are interchangeable as sources 
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of energy, with fats yielding 9 calories per gram, and protein and carbohydrates each yielding 4 
calories per gram (Slicker and Vermilyea, 2009). 
 
(i). Amino acids  
Amino acids prevent catabolism. Rapid administration of amino acids through TNA therapy 
attains earlier positive nitrogen balance in neonates and infants. It also dwindle the rate and 
severity of neonatal hyper glycaemia by enhancing endogenous insulin secretion and augmenting 
growth by enhancing the secretion of insulin and insulin-like growth factors (Colomb et al., 
2002, Denne, 2001; Ehrenkranz, 2007; Embleton et al., 2001). Protein are generally started at 
1g/kg/day in the form of crystalline amino acids up till 3rd to 4th post-natal day, afterwards it is 
increased to 3.0 g/kg/day in terms and 3.7 to 4.0 g/kg/day in the extremely low birth weight 
(ELBW) infants. Amino acids provide 4 kcal/g when oxidized for energy (Heiman and Schanler, 
2007; Khanna and Gopalan, 2007; Liusuwan et al., 2005; Saitoh et al., 2001; Shulman and 
Phillips, 2003; Valentine and Puthoff, 2007; Van Goudoever et al., 1995).  
 
Essential amino acids cannot be synthesized by the human body and are required to maintain and 
promote cell growth. All the commercially available solutions contain eight essential amino 
acids in varying proportions. Eminent essential amino acids are aspartate, glutamate, taurine, and 
tyrosine. Cysteine is also considered as conditionally essential in premature infants due to a 
theoretical insufficiency of enzymatic activity for the conversion of methionine to cysteine 
(Ganger and Craig, 1990; Heird and Gomez, 1996). Non-essential amino acids are those amino 
acids which can usually be produced by human body. These amino acids are used to increase the 
amount of nitrogen available from the solutions and the optimum ratio of essential to non-
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essential amino acids has yet to be agreed between workers. The nonessential amino acids are 
available as metabolites of other amino acids or precursors via enzymatic degradation (Camelo 
and Jorge, 1995). The semi- can be added in the TNAs if body does not synthesize them due to 
the patient's age or a disease state (Helms et al., 1999). 
 
(ii). Glucose 
Carbohydrate is delivered in 2.5 to 70% dextrose solutions that provide 3.4 kcal/g. Glucose is 
also called dextrose. Dextrose is the primary source of parenteral carbohydrate. Dextrose is 
needed by the central nervous system, white blood cells, red blood cells, and renal medulla. Each 
gram of hydrated dextrose used in parenteral nutrition yields 3.4 kcal. There is a relatively high 
energy requirement in the Extremely Low Birth Weight (ELBW) infants. In these neonates large 
and continuous source of glucose is required because of comparatively large body proportion of 
metabolically active organs i.e. liver, spleen, kidney and brain (Bolder et al., 2009, Valero et al., 
2001). In the ELBW the minimum Glucose Infusion Rate (GIR) is 6 mg/kg/min to maintain 
adequate energy for the brain and an additional 2-3 mg/kg/min of glucose per gram of protein 
intake is necessary to support protein deposition (Corridan et al., 2001). The maximum rate is 12 
to 13 mg/kg/min However, lower is applied if lipid is administered concurrently but in practice 
glucose administration is often limited by development of hyperglycaemia which is reported in 
20-80% of ELBW infants (Lloyd, 1998). Strategies for the management of hyperglycaemia in 
the ELBW include decreasing glucose administration, administering intravenous amino acids 
(which increase insulin secretion) and infusing exogenous insulin infusions (Bolder et al., 2009; 
Burrin et al., 2003; Corridan et al., 2001; Frankfort et al., 1993; Jones et al., 1993; Lloyd, 1998; 
Valero et al., 2001). 
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(iii). Fatty Acids 
Fat is needed to prevent essential fatty acid deficiency, serve as energy substrate and improve 
delivery of fat soluble vitamins. LBW infants may have undeveloped systems for fat metabolism. 
A number of clinical conditions inhibit lipid clearance e.g. infection, stress and malnutrition. 
Lipid is generally started at 1g/kg/day and steadily increased to a limit of 3 g/kg/day (sometimes 
up to 3.5g/kg/day in the ELBW). It is infused continuously over as much of the 24 hour period as 
practical and smaller doses are used in patients with infection, compromised pulmonary function 
or hyper bilirubinemia (Behrman et al., 1976; Chauhan et al., 2008; Herrera, 2002; Koletzko et 
al., 2005; Lima, 1989; Lima et al., 1988; Lopez-Herce et al., 2008; Takahashi and Sawaguchi, 
1983). 
 
Fat is administered as lipid emulsions of neutral triglycerides, primarily polyunsaturated fatty 
acids (PUFA) that are vital for normal growth and development, retinal development and 
function, brain development, and cell structure and function (Ehrenkranz et al., 2006). 
Intravenous lipid plays two separate roles in PN therapy. One is as a source of essential fatty 
acids as well as long chain polyunsaturated fatty acids. The other function of intravenous lipid is 
as energy substrate. Lipid emulsion has benefits over concentrated glucose solutions because of 
their isotonicity and greater energy density, the later meaning that less volume is required per 
calorie  (Ehrenkranz, 2007; Gramlich et al., 2004; Hay, 2008; Jadhav et al., 2007; Jr. Martinez, 
2005; Shulman, 2000; Smolkin et al., 2010; Steward and Pridham, 2002). 
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1.2.4 (b). Micronutrients 
Micronutrients are vitamins, electrolytes and trace minerals/elements. Vitamins and trace 
minerals are labeled as micronutrients because the body only requires them in very small 
amounts. Vitamins are organic substances that we ingest with our foods, and that “act as 
catalysts, substances that help to trigger other reactions in the body”. Trace minerals are 
inorganic substances that once ingested play a role in a “variety of metabolic processes, and 
contribute to the synthesis of such elements as glycogen, protein, and fats” (Slicker and 
Vermilyea, 2009). 
 
(i). Vitamins  
Infants on long-term PN therapy will generally require some vitamin supplementation. Vitamins 
are essential components of PN because they are necessary for normal metabolism and cellular 
function of the body. The American Society for Clinical Nutrition (ASCN) has established 
guideline which is shown in Table 1.1 (Greene et al., 1988). The vitamins which normally added 
into PN are: Vitamin A (Retinol), B1 (Thiamines), B2 (Riboflavine), B6 (Pyridoxine), B12 
(Cyanocobalamin), B (Nicotinamide), B (Biotin), B (Pantothenic acid), B (Folic acid), C 
(Ascorbic acid), D (Calciferol), E (Tocopherol) and vitamin K (Phytomenadione) (Lang, 1989; 
Porcelli et al., 2004; Van der Horst et al., 1989). 
 
(ii). Electrolytes  
Electrolytes in maintenance or therapeutic doses need to be added every day to the parenteral 
nutrition solution to preserve electrolyte homeostasis. Each patient’s requirements for individual 
electrolytes depend on the primary disease state, renal and hepatic functions, pharmacotherapy, 
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past intake, renal or extra renal losses, and nutritional status. Losses of extra renal electrolytes 
may be due to different diseases like diarrhea, vomiting, fistulas, or nasogastric suctioning. 
Dosage of every electrolyte should be made on patient needs (Biesalski et al., 2009; Hay, 2005; 
Schmidt, 2000).  
 
Potassium, sodium, and chloride are vital to human life and their needs are reliant on requisite 
losses and abnormal losses. Predictable and prudent intakes are entirely depended on accrual 
needs and fecal and urinary losses. Sodium and potassium can be given as chloride, lactate, or 
phosphate salts. Calcium, phosphorus, and magnesium are the most copious minerals in the 
body. They are closely interrelated to each other in metabolism, the formation of tissue structure, 
and function. Calcium and phosphorus needs may be greater in the neonate due to rapid skeletal 
bone development. The sufficiency of these valuable nutrients from PN admixtures has been 
widely studied in the premature population (Koo et al., 2000; Loui et al., 2002; Pelegano et al., 
1989; Schanler and Rifka 1994; Sievers et al., 2000; So and Ng, 2005; Vilelsis, 1987). 
 
(iii). Trace elements/minerals 
Trace elements are Zinc, Copper, Selenium, Chromium, Iron, Manganese, Cobalt, and 
Molybdenum. Trace elements are critical micronutrients that are metabolic cofactors and are 
vital for the appropriate functioning of numerous enzymatic pathways in neonates. Parenteral 
guidelines for molybdenum and iodine have not been established; however, these trace elements 
are available commercially (Pluhator-Murton et al., 1999; Van der Horst et al., 1989). The 
suggested amounts of zinc, copper, manganese, and chromium for neonates and infants are listed 
in Table 1.1. 
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Table 1.1. Daily requirement of nutrients in TNAs for neonates and infants (adapted from 
Brine E and Ernst J (2004), Newborn and Infant Nursing Reviews, 4, 133-155.) 
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Zinc is unanimously suggested from day one of PN therapy, while the rest trace minerals are 
commonly administered after three, five, or twelve weeks of PN without any significant enteral 
feeding (Hardy et al., 2001). Zinc requirements are increased in metabolic stress secondary to 
increased urinary losses and in gastrointestinal disease secondary to ostomy or diarrheal losses. 
ELBW infants need additional zinc than term infants (Pluhator-Murton et al., 1999). Selenium 
stores have been revealed to be depleted in patients receiving long-term parenteral nutrition or in 
those with thermal injury, acquired immunodeficiency syndrome, or liver failure. Therefore, 
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selenium should be added initially to the parenteral nutrition solution for patients with these 
disease states or conditions (Dworkin, 1994; Hardy et al., 2001; Hunt et al., 1984; Pluhator-
Murton et al., 1999). Recommended intravenous intake of trace elements for neonates and 
infants has been shown in Table 1.1.  
 
Parenteral iron supplementation may be delayed until two months of age in premature infants 
and three months of age in term infants but it can be considered for those infants who do not 
receive regular blood transfusions. Supplementation of iodide in TNAs may not be necessary 
because iodide needs may be met by other routine usages of topical iodide-containing 
disinfectants, detergents and other environmental sources (Al-Saleh et al., 2005; Baptista et al., 
1984; Blazewicz et al., 2010; Ekin et al., 2003; Leung, 1995; Leung, 1998; Leung et al., 1995; 
Ono et al., 1995; Papageorgiou et al., 2002; Rahman et al., 2009; Yanik et al., 2004). 
 
1.2.5. Antibiotics in neonates and infants 
In neonates, most common early-onset bacterial infections are caused by group B streptococci, 
enterococci, Enterobacteriaceae and Listeria monocytogenes. Coagulase-negative staphylococci, 
particularly Staphylococcus epidermidis are the main pathogens in late-onset (nosocomial) 
infections, especially in high-risk patients such as those with low birth weight, umbilical or 
central venous catheters or undergoing prolonged ventilation (Pacifici, 2011; Fanos and Agnola, 
1999). The primary objective of the pediatricians is to identity all potential cases of bacterial 
infections quickly and begin empirical antibacterial treatment immediately while waiting for the 
results of cultures and sensitivity tests. Combination therapy is often recommended for initial 
empirical treatment in children (McCracken, 1985; Fanos and Agnola, 1999). In early-onset 
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infections, an effective first-line empirical therapy is ampicillin plus a third-generation 
cephalosporin such as cefotaxime or ceftazidime. Combination therapy is particularly useful in 
neonatal meningitis (mean duration of treatment 14 to 21 days) and in patients at risk of 
nephrotoxicity (Fanos and Agnola, 1999).  
 
Neonatal sepsis is another life-threatening emergency and any delay in treatment may cause 
death. Initial signs of neonatal sepsis are slight and nonspecific (George, 1985; Yurdakök, 1998). 
Initial empirical antibiotic therapy for infants who developed sepsis, must cover the organisms 
associated with early-onset sepsis as well as hospital-acquired pathogens such as staphylococci, 
enterococci and Pseudomonas aeruginosa (Downie et al., 2012; Yurdakök, 1998). In cases 
showing increased risk of staphylococcal infections (e.g. presence of vascular catheter), 
Pseudomonas infections (e.g. presence of typical skin lesions), anti-staphylococcal or anti-
Pseudomonas agents may be preferred as an initial empirical therapy. In these situations, third-
generation cephalosporins alone or in combinations with penicillin or ampicillin have been used 
where they gave superior results (McCracken, 1985; Downie et al., 2012).  
 
1.2.6. Cephalosporins in neonates and infants 
Cephalosporins are appropriate alternatives when other commonly used antibiotics are not 
available. They have few potential advantages that make them distinguished from other 
antibiotics to treat various infections in children. Cephalosporins are more resistant to beta-
lactamases and are easy to administer and monitor as compared to penicillins (Cotton et al., 
2006; Bluestone et al., 2003). Cephalosporins have a wide margin of safety and are unlikely to 
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cause toxic signs even in overdose. Cephalosporins are drugs of choice against Pneumonia and 
urinary tract infections caused by Klebsiella. Cephalosporins also widely use in other infections 
like otitis media, acute sinusitis, pharyngitis, tonsillitis, lower respiratory tract infections and skin 
infections. In children cephalosporins are used for skin infections and acute bacterial otitis media 
(Bluestone et al., 2003).  
 
In this study we selected cephalosporins as in infants and neonates they are widely used group of 
antibiotics with a beta-lactam ring, resistant to beta-lactamases, and cover broad spectrum of 
gram-positive and gram-negative bacteria. Although all cephalosporins are potent but there are 
few infectious diseases in children where these drugs offer a unique advantage over other 
available antimicrobial agents (Charles et al., 2003; Cotton et al., 2006). Cephalosporins are also 
commonly prescribed either orally or parenterally for the treatment of numerous infections 
because of their wide safety margin compared with penicillins. Skin testing with a parent 
cephalosporin antibiotic is not necessarily required as compare to penicillins (Baek-Nam et al., 
2010). Penicillins are the antibiotics that most commonly induce severe or life-threatening IgE-
mediated reactions (anaphylaxis). Third-generation cephalosporins are generally well tolerated in 
neonates. When antibacterials are used in neonates, accurate determination of dosage is required, 
particularly for compounds with a low therapeutic index and in patients with renal failure (Fanos 
and Agnola, 1999).  
 
In few settings, third-generation cephalosporins are also combined with an aminoglycoside in 
places where aminoglycoside-resistance is high. Among the third-generation cephalosporins, 
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cefotaxime and ceftazidime possess wider anti-Pseudomonas activities (Yurdakök, 1998). 
Cefoperazone, cefotaxime and ceftazidime are parenteral products with efficacy in vitro against 
gram-positive cocci and gram-negative bacilli. Ceftazidime was first introduced for clinical use 
in the United States in 1985. This drug has excellent activity and often used in middle-ear 
infections in children and infants. Ceftazidime is drug of choice in surgical prophylaxis as well 
(Murki et al., 2010; Charles et al., 2003). Ceftazidime is first line of choice to treat Pseudomonas 
aeruginosa. Serious and life threatening infections like bacterial endocarditis are well treated by 
cephalosporins than other antibiotics. Cefuroxime and cefepime are widely utilized for the 
treatment of bronchitis, UTI's, community acquired pneumonia (Bluestone et al., 2003). 
Ceftriaxone and cefotaxime are drugs of choice in neonatal/childhood meningitis caused by 
Haemophilus influenzae. Cefepime is a fourth generation parenteral cephalosporin with excellent 
activity against gram-positive organisms and enhanced gram-negative activity including 
Pseudomonas aeruginosa (Capparelli et al., 2005; Charles et al., 2003). 
 
1.2.7. Administration of drugs in/with TNAs and parenteral nutrition 
In TPN therapy drugs are administered by three different methods i.e. Piggyback technique, 
using multiple lumen catheters and admixing drugs into volumetric chambers of IV fluids 
(Trissel et al., 1999). In IV Piggyback (abbreviated as IVPB) technique, a second IV medication 
or fluid is hung alongside the first fluid/drip and is attached to the first set of IV tubing through 
one of the injection ports that is below the drip chamber of the primary IV tube. These both 
fluids lines are connected by means of Y-site connectors (Russell et al., 2007). During 
simultaneous Y-site administration of two infusions, contact does not occur until they reach the 
common Y-site. Contact times of the admixtures from that point through the remainder of the 
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tubing until they reach the patient's bloodstream are typically 15 to 30 minutes but can go up to 
60 minutes or beyond in slow administration situations (Trissel et al., 1999). Second method 
where multiple lumen venous catheters are used is also expensive and risks of catheter-related 
bloodstream infection are more compared with single-lumen catheters (Zürcher et al., 2004).  
 
Sometimes separate administration of the drugs is not preferred because volume to be 
administered is more than 3 mL or it is advisable to give the medication over an extended period 
of time. In this case, we can simply inject the medication into one of the injection ports 
(volumetric chambers) on an IV line (Zürcher et al., 2004). Separate administration is not always 
possible and the line being used to infuse TPN continuously may be the only intravenous access 
available. Admixing of the drugs into volumetric chambers is cost effective, convenient and time 
saving but can only be possible if compatibility and stability of the admixing drugs with TPN 
admixtures is evident (Tanmoy and Ghosh, 2011). In this technique contact time of drug and 
TPN fluids is longer than Piggyback. In this method, desired drug is added into volumetric 
chamber by opening the sliding clamp. For drug addition, first disinfect the rubber injection port 
of the volumetric chamber and then incorporate drug by mixing gently. Regulate the flow rate of 
IV infusion accordingly and then close the clamp of the volumetric chamber (Russell et al., 
2007; Trissel et al., 1999; Zhang et al., 2000).  
 
Aggressive and early antimicrobial therapy with broad-spectrum antibiotics may be helpful in 
keeping the mortality rate low. It is preferable to start antimicrobial therapy with PN infusions 
for critical patients to avoid excessive catheter infections, which are difficult to treat and can 
potentially invite the risk of other complications (Puzovic and Hardy, 2007). Antibiotics with PN 
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therapy are also used to treat severe nosocomial or general infections either in adults or in 
children (Zaccardelli et al., 1990). Directives of the Joint Cornmission on Accreditation of 
Hospitals, USA in 1999 suggest that medication for intravenous use should be added to solutions 
in central pharmacies of the hospitals (Buchman, 2001). 
 
Addition of drugs to parenteral nutrition is always a potential source of instability. When a drug 
is added PN admixtures, the contact time between the drug as well as the excipients and 
nutritional components present in the formulation can be affected (Buchman, 2001). Because of 
the very complex physico-chemical composition of the PN admixtures, a long contact time 
represents a higher risk for drug nutrient interactions to develop (Zaccardelli et al., 1990). 
Turbidity, visual inspection, time, temperature and pH changes are standard assessments which 
should be done before administration into body. High performance liquid chromatography 
(HPLC), lipid particle counting and globule sizing are sophisticated electronic techniques which 
are normally used to investigate incompatibility, instability or different sorts of drug interactions 
(Puzovic and Hardy, 2007). 
 
The addition of drugs to PN admixtures or their co-administration requires thorough knowledge 
of the stability of drugs within these complex solutions (Puzovic and Hardy, 2007). Antibiotic 
stability has been assessed in relatively few publications, and in most of these, stability and 
compatibility studies have been limited to mixtures of the antibiotics with normal saline or 5% 
dextrose (Pluhator-Murton et al., 1999). In past, amino acid solutions of varying composition in 
combination with vitamins, minerals, glucose, and electrolytes have been utilized in intravenous 
infusions (Buchman, 2001). Relatively fewer information on the stability and compatibility of 
  
24 
 
drugs in intravenous PN admixtures is available in product information booklets, package 
leaflets and in the published scientific literature (Puzovic and Hardy, 2007). The importance of 
developing a systematic approach to the study of drug incompatibility and stability in parenteral 
solutions is highlighted by the present study. 
 
Establishment of an intravenous product’s stability and compatibility with various intravenous 
solutions allows greater flexibility and convenience for administration. In general, antibiotics and 
PN admixtures should be administered through separate intravenous lines, however, in certain 
clinical situations it would be advantageous to mix the antibiotic in/with PN admixtures or to 
administer them in Y-site with PN admixtures (Zaccardelli et al., 1990). 
 
Previous studies addressing antibiotic compatibility with PN admixtures have used relatively 
dilute antibiotic solutions (i.e. ampicillin 1 mg/mL), or PN admixtures without electrolytes. Such 
data would only be valid for antibiotics administered in very low concentrations which is not 
useful especially when there is a need of high antibiotics doses (Mirtallo, 2004). This may be the 
reason for the different results of previous compatibility studies. Therefore, diluting each 
antibiotic dose in 50 to 100 mL of solution, as is often done in adult settings, may be acceptable. 
Unfortunately, we often do not afford the luxury of such fluid volumes in pediatric patients. The 
antibiotic infusion time and volume may also have an impact on the results (Niël-Weise et al., 
2008, Watson, 1985).  
 
Parenteral Nutrition has become an accepted method for the administration of nutrients to 
patients. However, it is not without risks and complications (Dunham et al., 1991). Patients 
